Covalent modification of the oncogene product Mdm2 by the ubiquitin-related protein SUMO1 protects it from ubiquitination and enhances its E3 ligase activity towards p53 in vitro. Disappearance of ...

However, loss of p53 tumour-suppressor activity can also occur through amplification of MDM2. As MDM2 is a negative regulator of p53, this promotes p53 degradation and inhibits p53 tumour ...

an aggressive tumour type that starts in fat cells and is characterised by amplification of the MDM2 gene. At the moment, the only treatment option is chemotherapy, but this typically stops ...